Explore our core portfolio of validated peptide sequences, backed by multi-ton manufacturing infrastructure and rigorous analytical validation in Hangzhou, China.
A comprehensive examination of structural engineering, cardiolipin stabilization mechanisms, and modern synthetic peptide chemistry requirements for pharmaceutical-grade material.
SS-31 (also designated as Elamipretide, Bendavia, or MTP-131; CAS Number 736992-21-5) represents a synthetic cell-permeable aromatic-cationic tetrapeptide with the structural motif D-Arg-Dmt-Lys-Phe-NH2. Incorporating 2',6'-dimethyltyrosine (Dmt) alongside D-arginine provides steric stabilization and exceptional resistance to systemic aminopeptidases.
Unlike conventional antioxidants that scavenge radical species ubiquitously in cytoplasm, SS-31 selectively concentrates >1,000-fold in the inner mitochondrial membrane (IMM). It selectively associates with cardiolipin via electrostatic interactions with phosphate heads and hydrophobic insertion, optimizing electron transport chain flux.
The industrial synthesis of SS-31 presents distinct synthetic bottlenecks. Incorporating sterically hindered non-canonical residues like 2',6'-dimethyltyrosine demands proprietary coupling activation strategies to suppress epimerization and avert deletion peptide impurities (such as des-Dmt or des-Arg variants).
Analyzing clinical pipeline maturation, supply chain dependencies, and the shifting manufacturing paradigm from early research quantities to multi-kilogram cGMP batches.
The clinical trajectory of SS-31 has gained global momentum through target indications in ultrarare mitochondrial disorders, most prominently Barth syndrome (tafazzin gene mutation causing cardiolipin deficiency). Regulatory review pathways under FDA Priority Review and Orphan Drug designations have created high commercial demand for validated, impurity-free API suppliers capable of passing stringent audit inspections.
While originally focused on rare genetic disorders, commercial R&D has rapidly bifurcated into massive chronic disease markets: heart failure with preserved ejection fraction (HFpEF), ischemia-reperfusion injury in cardiac revascularization, dry age-related macular degeneration (AMD) / geographic atrophy, and diabetic kidney disease. This expansion necessitates multi-kilogram to commercial metric-ton supply agreements.
Innovator biotech companies in North America and Western Europe increasingly partner with integrated peptide manufacturers in China like Thinheal Pharma-Tech. China’s robust raw material supply chain (providing cost-efficient fluorenylmethoxycarbonyl [Fmoc] amino acid building blocks) coupled with advanced analytical cGMP platforms enables a 40–60% reduction in developmental lead times.
Deep dive into organ-specific mitochondrial repair mechanisms, dosage ranges, formulation considerations, and clinical therapeutic frontiers enabled by SS-31 API.
In acute myocardial infarction and heart failure, disruption of mitochondrial cristae drives apoptotic cardiomyocyte loss. SS-31 preserves cardiolipin alignment, enhances Complex I and III coupling efficiency, and mitigates reperfusion injury when infused intravenously prior to percutaneous coronary intervention (PCI).
Retinal pigment epithelial (RPE) cells demonstrate among the highest metabolic rates in human physiology. Oxidative breakdown of IMM cardiolipin causes mitochondrial fragmentation, resulting in Geographic Atrophy in AMD. SS-31 administered via subcutaneous or intravitreal delivery shields photoreceptors from photo-oxidative stress.
Proximal tubular cells are heavily packed with mitochondria to fuel ATP-dependent solute reabsorption. Ischemic or nephrotoxic insult (e.g., cisplatin, contrast media) triggers immediate cardiolipin peroxidation. SS-31 treatment accelerates tubular regeneration and halts tubulointerstitial fibrosis.
Mitochondrial bioenergetic failure is a cardinal hallmark of Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). SS-31 traverses blood-brain barrier models, restores synaptic ATP levels, diminishes neuroinflammatory microglial activation, and protects dopaminergic neurons from 1-methyl-4-phenylpyridinium (MPP+) toxicity.
Unifying nearly two decades of peptide synthesis expertise, automated multi-ton manufacturing bases, and complete CMC documentation for global pharmaceutical procurement.
Founded in 2019, Hangzhou Thinheal Pharma-Tech Co., Ltd. operates a state-of-the-art biopharmaceutical campus in Hangzhou's Heda Medicine Valley. Our multi-ton synthesis facility utilizes automated 500L to 3000L solid-phase peptide reactors (SPPS) engineered for precise thermal control, inert nitrogen sparging, and high coupling yields across complex peptide chains.
Purification of basic peptides with multiple positive charges represents a specialized art. Thinheal runs industrial-scale preparative DAC (Dynamic Axial Compression) columns up to 1000mm diameter. We employ ion-exchange chromatography protocols allowing customized counter-ion replacement (Acetate, Chloride, or low-TFA salt forms) matching client specifications.
Every commercial or research batch is released under strict QA oversight. Thinheal supplies complete analytical documentation packets: High-Resolution UPLC-MS sequence confirmation, RP-HPLC purity, residual organic solvents (USP <467> GC-HS), elemental impurity analysis (ICH Q3D ICP-MS), amino acid composition analysis, and kinetic turbidimetric endotoxin assays.
| Test Parameter | Standard Specification | Analytical Methodology | Compliance Status |
|---|---|---|---|
| Appearance | White to off-white lyophilized amorphous powder | Visual inspection (EP / USP) | ✓ Conforms |
| Chemical Purity (RP-HPLC) | ≥ 98.50% (Commercial Grade ≥ 99.00%) | Reverse Phase HPLC (C18, UV 220nm) | ✓ Conforms |
| Mass Spectrometry (MS) | 639.80 ± 1.0 Da ([M+H]+ = 640.80 m/z) | ESI-MS / High-Res Q-TOF | ✓ Conforms |
| Individual Related Impurities | ≤ 0.50% each (Single largest known/unknown) | High-Resolution Gradient RP-HPLC | ✓ Conforms |
| Dmt / D-Arg Diastereomers | ≤ 0.20% (Chiral inversion impurities) | Chiral Stationary Phase HPLC | ✓ Conforms |
| Counter-Ion Content | Acetate: 4.0% - 10.0% / TFA ≤ 0.10% (Optional Form) | Ion Chromatography (IC) | ✓ Conforms |
| Water Content (Karl Fischer) | ≤ 5.0% (w/w) | Coulometric Karl Fischer Titration | ✓ Conforms |
| Bacterial Endotoxin | ≤ 5.0 EU/mg (Parenteral grade ≤ 0.5 EU/mg) | Kinetic Turbidimetric / LAL Test | ✓ Conforms |
Addressing the major pharmaceutical delivery hurdles of hydrophilic peptides: green manufacturing, hybrid phase synthesis, and oral bioavailability engineering.
While solid-phase peptide synthesis (SPPS) reigns supreme for small clinical lots, commercial metric-ton supply requires sustainable economics. Thinheal is actively validating liquid-phase fragment condensation (LPPS) protocols. By synthesizing protected dipeptide segments (Fmoc-D-Arg-Dmt-OH and H-Lys(Boc)-Phe-NH2) in solution and executing convergence coupling, overall solvent footprint (DMF/NMP) drops by over 65%.
Because SS-31 possesses a +3 net positive charge at physiological pH, intestinal mucosal permeability is restricted. Thinheal collaborates with innovative formulation developers evaluating permeation enhancers (such as SNAC - sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) and lipid nanoparticle encapsulation to transition from daily subcutaneous injections to once-daily oral tablets.
Peptide APIs are susceptible to hydrolytic deamidation and oxidation under improper temperature custody. Thinheal maintains an end-to-end monitored cold-chain export workflow (-20°C validated active-monitored shipping) serving four global sales desks (North America, Russia & CIS, Pan-Asia, Middle East), ensuring zero loss of enantiomeric purity upon arrival.
Authoritative technical, analytical, and supply chain answers curated for biopharma procurement heads, medicinal chemists, and QA auditors.
Discover our complementary line of clinical metabolic, neuro-active, and hormone analogues synthesized at Thinheal's cGMP facilities in Hangzhou.
Direct communication with our regional pharmaceutical engineering and regulatory desks across major pharmaceutical markets.
Dedicated technical lead for FDA IND filings, DMF submissions, and transatlantic cold-chain shipping logistics.
Bilingual registration assistance, customs customs clearance protocol support, and specialized regional compliance.
Headquartered at Heda Medicine Valley, Hangzhou. Fast route turnaround for contract development and high-volume generic supply.
Thin